Insight

Vivek Subbiah: SERENA-1 monotherapy results in Annals of Oncology

Photo from annalsofoncology.org

May 9, 2024, 11:35

Vivek Subbiah: SERENA-1 monotherapy results in Annals of Oncology

Quoting Vivek Subbiah on X: .

“A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results – Annals of Oncology.”

Read further.
Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA).

He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Annals of Oncology Breast Cancer cancer Erika Hamilton OncoDaily Oncology Sarah Cannon Research Institute SERD camizestrant SERENA-1 SERENA-1 monotherapy results Vivek Subbiah

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage